DNA-hypermethylation of SOCS genes in breast, ovarian, squamous cell and hepatocellular carcinoma has led to speculation that silencing of SOCS1 and SOCS3 genes might promote oncogenic transformation of epithelial tissues. To examine whether transcriptional silencing of SOCS genes is a common feature of human carcinoma, we have investigated regulation of SOCS genes expression by IFNc, IGF-1 and ionizing radiation, in a normal human mammary epithelial cell line (AG11134), two breastcancer cell lines (MCF-7, HCC1937) and three prostate cancer cell lines. Compared to normal breast cells, we observe a high level constitutive expression of SOCS2, SOCS3, SOCS5, SOCS6, SOCS7, CIS and/or SOCS1 genes in the human cancer cells. In MCF-7 and HCC1937 breast-cancer cells, transcription of SOCS1 is dramatically up-regulated by IFNc and/or ionizing-radiation while SOCS3 is transiently down-regulated by IFNc and IGF-1, suggesting that SOCS genes are not silenced in these cells by the epigenetic mechanism of DNAhypermethylation. We further show that the kinetics of SOCS1-mediated feedback inhibition of IFNc signaling is comparable to normal breast cells, indicating that the SOCS1 protein in breast-cancer cells is functional. We provide direct evidence that STAT3 pathways are constitutively activated in MCF-7 and HCC1937 cells and may drive the aberrant persistent activation of SOCS genes in breast-cancer cells. Our data therefore suggest that elevated expression of SOCS genes is a specific lesion of breast-cancer cells that may confer resistance to proinflammatory cytokines and trophic factors, by shutting down STAT1/STAT5 signaling that mediate essential functions in the mammary gland.
DNA-hypermethylation of SOCS genes in breast, ovarian, squamous cell and hepatocellular carcinoma has led to speculation that silencing of SOCS1 and SOCS3 genes might promote oncogenic transformation of epithelial tissues. To examine whether transcriptional silencing of SOCS genes is a common feature of human carcinoma, we have investigated regulation of SOCS genes expression by IFNc, IGF-1 and ionizing radiation, in a normal human mammary epithelial cell line (AG11134), two breastcancer cell lines (MCF-7, HCC1937) and three prostate cancer cell lines. Compared to normal breast cells, we observe a high level constitutive expression of SOCS2, SOCS3, SOCS5, SOCS6, SOCS7, CIS and/or SOCS1 genes in the human cancer cells. In MCF-7 and HCC1937 breast-cancer cells, transcription of SOCS1 is dramatically up-regulated by IFNc and/or ionizing-radiation while SOCS3 is transiently down-regulated by IFNc and IGF-1, suggesting that SOCS genes are not silenced in these cells by the epigenetic mechanism of DNAhypermethylation. We further show that the kinetics ofIntroduction Development of the mammary gland is regulated by factors that coordinate proliferation, differentiation, maturation and apoptosis of mammary epithelial cells. Exquisite control of the initiation, strength and duration of signals from the diverse array of cytokines and growth factors in mammalian breast is essential to the timely initiation of the menstrual cycle, lactation or breast lobule involution (Medina, 2005) . Germ-line mutations or epigenetic mechanisms that silence proteins that regulate cytokine activities underlie breast tumorigenesis. This has led to interest in cytokinesignaling mechanisms and how they can be exploited to pharmacologically inhibit aberrantly activated human cancer cells.
Most growth factors/cytokines implicated in pathogenesis of breast cancer share the common feature of activating STAT pathways (Darnell, 1997; Clevenger, 2004) . The 6-member STAT family of transcription factors links cytokine signals to transcriptional events that regulate cell-cycle progression and apoptosis (Bowman et al., 2000; Darnell, 2005) . The strength and duration of STAT signals are regulated by suppressor of cytokine-signaling (SOCS) proteins, an 8-member family of cytokine-inducible proteins that attenuate or terminate cytokine/growth factor signals (Hilton, 1999) . If not properly regulated, constitutive activation of STAT pathways can induce oncogenic transformation, tumor cell invasion and metastasis (Darnell, 2005; Haura et al., 2005) . In fact, defects in negative-feedback regulation of STAT pathways have been identified in diverse tumors (Sutherland et al., 2004; Campbell, 2005; Haura et al., 2005; Sultan et al., 2005) . Recently, hypermethylation of the SOCS1 or SOCS3 gene has been reported in lung cancer (He et al., 2003) , breast and ovarian cancer (Sutherland et al., 2004) , squamous cell carcinoma of the head and neck (Weber et al., 2005) and hepatocellular carcinoma (Niwa et al., 2005) . This has led to the speculation that SOCS genes are transcriptionally silenced during oncogenic transformation of epithelial carcinoma cells and that defective expression of SOCS proteins, with subsequent loss of feedbackregulation, may contribute to tumor progression and metastasis (Rottapel et al., 2002; He et al., 2003) .
In this study, we have utilized a panel of tumor cell lines to investigate whether: (i) SOCS genes are transcriptionally silent in breast and prostate cancer cells; (ii) whether negative-feedback responses mediated by SOCS proteins are normal or defective in breast-cancer cells. We show that SOCS genes are constitutively expressed at relatively high levels in human breast-cancer cells, indicating that SOCS promoters are not transcriptionally silent. Our data further indicates that elevated SOCS expression in breast-cancer cells derives from persistent activation of SOCS genes in response to constitutive activation of STAT3 pathways in these cells.
Results

SOCS genes are transcriptionally active and constitutively expressed in breast-cancer cells
We utilized two breast-cancer cell lines (MCF-7 and HCC1937) and a normal mammary epithelial cell line (AG11134) to examine whether transcriptional silencing of SOCS genes occurs frequently in human breast carcinoma cells. As a positive control, we also analysed a B-lymphoblastoid cell line (HCC1937BL) that constitutively expresses high levels of most SOCS family genes (unpublished data). The RPA data presented in Figure 1a reveals that most SOCS genes are constitutively expressed at high levels in the breast-cancer cells relative to the normal breast cells. Although SOCS1, SOCS2 and SOCS3 genes are known to be hypermethylated in MCF-7 cells (He et al., 2003; Sutherland et al., 2004) , this result clearly reveals that these genes are not transcriptionally silent in MCF-7 cells. In addition, SOCS2, SOCS3, SOCS5, SOCS6 and SOCS7 genes are expressed in HCC1937 cells at levels comparable to MCF-7 (Figure 1a) . We also analysed SOCS expression in a normal prostate cell line (RWPE-1) and three prostate cancer cell lines (LNCaP, and as shown in Figure 1b , SOCS1, SOCS3, SOCS5 and CIS genes are transcriptionally active in these cell lines, albeit to varying extent. Both the PC-3 and DU-145 express levels of SOCS1, SOCS3, SOCS5, CIS genes that are significantly lower than the normal RWPE prostate cells. On the other hand, LNCaP cells express SOCS1, SOCS3, SOCS5 and CIS at levels comparable to RWPE, underscoring the fact that this carcinoma cell line exhibits a normal pattern of SOCS genes expression. These results indicate that SOCS genes are not silenced in all breast or prostate cancer cells.
Interferon-g activates transcription of SOCS genes in MCF-7 or HCC1937 cells To demonstrate that SOCS genes are not silenced in breast-cancer cells, it is not only important to show that SOCS genes are constitutionally expressed, but also that the cancer cells are capable of inducing transcription of SOCS genes in context of classical feedback response to growth-factor/cytokine signaling. To this end, MCF-7, HCC1937 and AG11134 cells were starved for 12 h, stimulated with IFNg and then analyzed for induction of SOCS expression. We show that IFNg activates transcription of SOCS1 and CIS in these cells. On the other hand, SOCS3 expression is induced in AG11134 but downregulated in the two cancer cell lines at the 120-min time point (Figure 2 ). However, moderate induction of SOCS3 is also observed in HCC1937 at 30-min. The complex pattern of SOCS5 or SOCS6 expression observed is consistent with the fact that these SOCS members are not classic feedback regulators of cytokinesignaling and the mechanism of transcriptional regulation of both genes is poorly understood. These results clearly suggest that SOCS promoters of the breastcancer cells are responsive to cytokine-induced transcriptional regulation as indicated by upregulation of SOCS1 and CIS genes and downregulation of SOCS3 gene.
Duration of STAT signals is inversely correlated with SOCS levels in breast cells
To investigate whether SOCS proteins in breast-cancer cells are capable of mediating feedback-inhibition of cytokine-signaling, we stimulated MCF-7, HCC1937, HCC1937BL and AG11134 cells with IFNg for varying amounts of time and determined the kinetics of STAT1 activation and subsequent termination of the STAT1 signal. STAT1 activation, as indicated by phosphorylation of STAT1 (pSTAT1), is not detected in unstarved and unstimulated cells (Figure 3a ), suggesting that STAT1 pathway is not constitutively activated in these cells. On the other hand, relatively high levels of pSTAT1 are detected in MCF-7, HCC1937 and AG11134 following 30 min stimulation by IFNg ( Figure 3a ). However, after 120 min pSTAT1 is considerably lower in MCF-7 cells while the STAT1-signal is still intense in AG11134 that has the lowest levels of endogenous SOCS expression. In contrast, after 30 min only a modest level of pSTAT1 is detected in HCC1937BL with the highest endogenous SOCS expression and duration of STAT1 signal is short-lived ( Figure 3a) . However, after 3 h pSTAT1 is no longer detectable in any of the stimulated cells (data not shown), suggesting a complete termination of the STAT signal. To examine whether termination of STAT1 signal correlates temporally with induction of SOCS transcription, we quantified SOCS1 and SOCS3 expression during the course of stimulation with IFNg. As noted in Figure 3b , there is a 7.5-fold increase in SOCS1 expression in AG11134 and a threefold increase in MCF-7 cells in response to IFNg. The lower foldincreases noted for HCC1937BL and MCF-7 reflects the fact that absolute level of SOCS1 transcripts is higher in these cells ( Figure 1a ) and calculation of foldchanges is based on comparison to the basal level of SOCS expression. Conversely, the relatively higher fold-increase noted for AG11134 and HCC1937 (40-fold) derives from their low endogenous SOCS1 levels. Similar to data presented (Figure 2 ), expression of SOCS1 and SOCS3 is upregulated by IFNg in AG11134 while SOCS3 transcription is repressed in the breastcancer cells (Figure 3b) . These results reveal a fundamental difference in the response of SOCS3 promoter to IFNg-induced STAT-signaling in normal breast and breast-cancer cells and suggest that duration of STAT1-signals is inversely correlated with steady-state SOCS mRNA levels in the cells.
Growth factor signals downregulate transcription of SOCS genes in breast-cancer cells
In view of the high endogenous levels of SOCS expression in breast-cancer cells (Figure 1) , it was of interest to examine whether activation of STAT pathways by growth factors or their feedback regulation is defective in these cells. Whole cell protein extracts, RNA and nuclear extracts from MCF-7 or HCC1937 cells stimulated with IGF-1 were therefore analysed for STAT activation or SOCS gene expression by Western blotting, EMSA or real-time polymerase chain reaction (PCR). Detection of pSTAT1 and pSTAT3 in stimulated MCF-7 and HCC1937 (Figure 4a ), suggests that high basal level of SOCS expression does not prevent activation of these pathways in breast-cancer cells. We provide evidence that STAT3 pathway is constitutively We show that the SIE GAS probe interacts with activated STAT1 and STAT3 in IFNg-stimulated cells (Figure 4c ) and super-shift assays reveal that the IGF1-induced DNA-binding activity is pSTAT3 (Figure 4d) . Surprisingly, pSTAT3 but not pSTAT1 is able to bind DNA despite the fact that both proteins are activated in MCF-7 and HCC1937 cells following IGF-1 stimulation (see Figure 4a and d) . This suggests that IGF-1 signals may interfere with DNA-binding by pSTAT1, thereby inhibiting activation of STAT1-dependent anti-proliferative pathways. Of particular interest is our finding that stimulation of MCF-7 or HCC1937 by IGF-1 induces a transient downregulation of SOCS1 and SOCS3 gene expression (Figure 4d and e) that is followed by a gradual increase to their steady-state levels (data not shown). Although the functional implication of this is unknown, similar observations have been made in lymphocytes where the initiation of lymphocyte proliferation and differentiation is coupled to a downregulation of SOCS3 (Yu et al., 2004) . Interestingly, the downregulation of SOCS1 following stimulation with IGF-1 is in stark contrast to the response to IFNg. Whereas IGF-1 represses transcription of SOCS1 (Figure 4e ), the SOCS1 gene is transactivated by IFNg (Figure 3) .
Expression of SOCS1 gene is regulated by IRF-1 in BRCA1-deficient breast-cancer cells Transcriptional activation of SOCS1 by IFNg requires IRF-1 (IFN regulatory factor 1) and STAT1 (Saito et al., 2000) . Recently, STAT1 was shown to collaborate with BRCA1 in activating genes that mediate growth inhibitory and pro-apoptotic effects of IFNg and among these are p21
WAF1 and IRF-1 (Ouchi et al., 2000) . We, therefore, investigated whether similar to SOCS1, if expression of other IFNg/STAT1-inducible genes is also defective in BRCA1-deficient HCC1937 cells. We show that the amount of IRF-1 or p21 WAF1 protein detected in HCC1937 is low compared to MCF-7, HCC1937BL or AG11134 cells (Figure 5a ), suggesting that the low endogenous SOCS1 expression in BRCA1-deficient HCC1937 cells (Figure 1a ) may derive in part from a global defects in expression of BRCA1/STAT1 regulated genes. To directly examine whether the IRF-1 and p21
WAF1 genes are transcriptionally silent, we stimulated HCC1937 cells with IFNg or g-irradiation, two agents that are known to induce transcription of these genes. As shown in Figure 5b , IFNg induces significant increase in IRF-1 expression and peak of IRF-1 protein expression correlates temporarily with maximum induction of SOCS1 expression in HCC1937 cells (Figure 2) . Thus, although BRCA1 is required for optimal expression of IRF-1 and SOCS1, the requirement of BRCA1 can be overcome by increasing the intensity of STAT1-signal in HCC1937 cells. Interestingly, whereas expression of IRF-1 and p21 WAF1 genes is upregulated by g-radiation (Figure 5c ), the p21 WAF1 promoter is not responsive to activation by IFNg (Figure 5b ). Nonetheless, the observed effects of g-irradiation is consistent with reports showing that IRF-1 and p53 converge functionally to upregulate p21 WAF1 in response to genotoxic stress (Tanaka et al., 1996) . As SOCS1 and p21 WAF1 genes are regulated by IRF-1 (Coccia et al., 1999) , these results suggest that the low basal expression of SOCS1 and p21 WAF1 genes derive indirectly from defects in IRF-1 expression in HCC1937 cells. The data also underscore the fact that the IRF-1, SOCS1, p21 WAF1 promoter can be active or silent depending on the physiological state of the cell but are clearly not 'transcriptionally silent' in HCC1937 cells.
Discussion
Recent reports of aberrant DNA-hypermethylation of SOCS genes in a number of breast-cancer cell lines have led to the suggestion that SOCS genes are silenced during transformation of breast epithelium and may therefore contribute to development of breast cancer (He et al., 2003; Sutherland et al., 2004) . The data presented here does not support that claim. Compared to non-malignant mammary epithelial cells, expression of SOCS2, SOCS3, SOCS5, SOCS6, SOCS7 and/or SOCS1 genes is elevated in MCF-7 and HCC1937, two cell lines that serve as prototypic breast-cancer cell types. Both SOCS1 and SOCS3 promoters are shown to be highly responsive to regulation by cytokine or growth factor signals, even in breast-cancer cells with hypermethylated CpG islands in SOCS1, SOCS2 and SOCS3 promoters (He et al., 2003; Sutherland et al., 2004) . In addition, we have shown that the mechanism of SOCSmediated feedback inhibition of cytokine signaling is not defective in MCF-7 and HCC1937 and comparable to normal breast cells. Our results showing overexpression of SOCS genes in breast-cancer cells is clearly at variance with another report suggesting that SOCS1 and SOCS2 genes are transcriptionally silent in breastcancer cells (He et al., 2003; Sutherland et al., 2004) . However, our data is in line with clinical findings of elevated SOCS1, SOCS2, SOCS3, CIS expression within in situ ductal carcinomas, infiltrating ductal carcinomas, human tumor tissues and in 10 additional breast-cancer cell lines: In fact, CIS is elevated in all/ most breast-cancer lines and may drive proliferation by activation of ERK (Raccurt et al., 2003) .
The most compelling evidence in support of the notion that SOCS genes are silenced by DNA-hypermethylation in breast-cancer cells is based on experiments in which SOCS1 expression was re-activated in breast-cancer cell lines following treatment with 5-aza-2 0 -deoxycytidine (Sutherland et al., 2004) . However, WAF1 mRNA transcripts in g-irradiated AG11134 or HCC1937 cells.
treatment of cancer cells with the methylase inhibitor, 5-aza-2 0 -deoxycytidine, has been shown to inhibit growth of cancer cells by activating interferon/STAT1-signaling pathways (Missiaglia et al., 2005) . Thus, enhanced expression of SOCS1 or 5-aza-2 0 -deoxycytidine-induced growth suppression of breast-cancer cells noted in the study by Sutherland et al. may well have derived from activation of STAT1, a transcription factor that is the primary inducer of SOCS1 (Hilton, 1999) . Discerning the exact mechanism responsible for re-activating SOCS1 expression in the 5-aza-2 0 -deoxycytidine-treated cells is further confounded by the fact that transcription factors that regulate the SOCS1 gene may also be silenced by DNA-hypermethylation in breast-cancer cells. For example, the BRCA1 gene that has been implicated in breast tumorigenesis (Welcsh et al., 2002) is also a target of DNA methylases (Wei et al., 2005) and hypermethylation of the BRCA1 gene occurs in 7-31% of sporadic breast and ovarian cancers (Catteau and Morris, 2002) . It is therefore, difficult to rule out that the re-activation of SOCS1 expression by 5-aza-2 0 -deoxycytidine results from demethylation of other silenced genes that constitute the CpG island methylator phenotype in breast cancer (Issa, 2004) .
The etiology of breast cancer is still not well understood. Although overexpression or silencing of SOCS genes may be involved, the most common genetic lesion associated with development of breast cancer is germline mutation or epigenetic silencing of the BRCA1 gene (Cui et al., 1998; Aprelikova et al., 2001) . BRCA1 is a potent transcriptional activator with roles in DNA damage repair, cell cycle checkpoint control and apoptosis (Andrews et al., 2002; Welcsh et al., 2002) and has recently been shown to collaborate with STAT1 in transcriptional activation of growth-inhibitory and pro-apoptotic genes (Ouchi et al., 2000) . As transcription of the SOCS1 gene is regulated by IRF-1 (Saito et al., 2000) and expression of IRF family of transcription factors require synergism between STAT1 and BRCA1 (Andrews et al., 2002) , we used the BRCA1-deficient HCC1937 to investigate whether expression of SOCS1 gene requires BRCA1. Analysis of HCC1937 cells reveals that IRF-1 expression is defective (Figure 5a ) and may account for low SOCS1 expression in this breast-cancer cell line (Figure 1a) . However, treatment of HCC1937 with IFNg significantly enhances IRF-1 and SOCS1 expression (Figures 2, 3b and 5b) , indicating that optimal expression of the IRF-1 and SOCS1 genes requires BRCA1 as a co-activator of STAT1. This requirement can however, be overcome by increasing the intensity of STAT1-signaling in HCC1937 cells. In fact, expression of p21
WAF1
, another IFNginducible gene, is also defective in HCC1937 cells (Figure 5a ), suggesting that the low SOCS1 expression in HCC1937 maybe due to global defects in BRCA1/ STAT1-dependent transcription.
In AG11134 cells, SOCS3 mediates negative-feedback regulation of IGF-1 signaling and following termination of growth signal SOCS3 expression returns to its basal level, consistent with its role in inhibiting JAK-kinases and promoting apoptosis of differentiated epithelial cells in the mammary gland (Le Provost et al., 2005) . Although SOCS3 is elevated in MCF-7 and HCC1937 (Figure 1a) , it does not exert efficient feedback-regulation on STAT3-signaling as evidenced by constitutive activation of STAT3 in these breast-cancer cells (Figure 4b) . Interestingly, stimulation of MCF-7 or HCC1937 by IGF-1 activates both STAT1, as well as, STAT3 and whereas activated STAT3 is capable of binding DNA, DNA-binding by activated STAT1 is inhibited (Figure 4d) . A similar finding has been made in a T-cell lymphoma (Brender et al., 2005) . In that study, malignant cells expressed high levels of SOCS3 but were unable to inhibit and terminate STAT3-signaling. Instead, SOCS3 functioned as a tumor promoter by inhibiting IFNa/STAT1-mediated growth inhibition without affecting cell growth or apoptosis (Brender et al., 2005) . Our results suggest that elevated SOCS3 may also function as a tumor promoter in breast cancer and inability of SOCS3 to terminate STAT3-signaling in MCF-7 and HCC1937 cells is consistent with the association of constitutive STAT3 activation with primary tumors of high-risk breast cancer patients (Gritsko et al., 2006) .
Although DNA-hypermethylation is widely recognized as a common feature of human neoplasia (Issa, 2004) , this epigenetic mechanism also occurs as part of normal aging process and most often, CpG islands that are methylated in cancer cells are also methylated in normal cells during aging (Toyota et al., 1999) . Our data suggest that DNA-hypermethylation of SOCS genes observed in breast carcinoma may be similar to the hypermethylation of SOCS3, P16, p21 WAF1 or PTEN gene in advanced ovarian cancer (Teodoridis et al., 2005) . In that study, the hypermethylation had no effects on the biological activities of these proteins. Analysis of SOCS expression in BRCA1-deficient HCC1937 is particularly instructive as it reveals that transcriptional-silencing of SOCS1 gene derives from defects in the transcription of a transcription factor upstream of SOCS1 activation pathway and not due to DNA-hypermethylation. On the other hand, our data suggests that increased expression of SOCS genes is a specific lesion of breast-cancer cells and may derive from constitutive activation of STAT3 pathways (Figure 4b ). Additional studies are needed to firmly establish that elevated endogenous SOCS expression in breast cancer derives from aberrant host/tumor response to autocrine/ paracrine stimulation of STAT3 pathways. However, its consequence appears to be in conferring resistance to proinflammatory cytokines by shutting down STAT1 signaling pathway that mediate essential functions in immune-surveillance.
Materials and methods
Cells and culture conditions
The breast-cancer cell lines (MCF-7, HCC1937), prostate cancer cell lines (LNCaP, PC-3 and DU-145), non-malignant prostate cell line (RWPE-1) and BRCA1
À/ þ lymphoblastoid cell line (HCC1937BL) were obtained from American Type Culture Collection (Manassas, VA, USA). The normal human mammary epithelial cells AG11134 were from the Aging Cell Repository (National Institute of General Medical Sciences Coriell) (details relating to culture conditions for the cell lines is published as supporting information on the Oncogene website).
Quantitative real-time PCR analysis
Real-time 5 0 -nuclease fluorogenic RT-PCR analysis was performed on an ABI 7700 (PE Biosystems, Foster City, CA, USA) using DNase-treated RNA, SuperScript II Reverse Transcriptase (RT) (Invitrogen Life Technologies, Gaithersburg, MD, USA), and oligo(dT) 12-16 as previously described (Yu et al., 2004 ) (primers, probes and details of the quantitative real-time PCR procedure are published as supporting information on the Oncogene website).
Ribonuclease protection assay
Ribonuclease protection assay (RPA) was performed with RNA (10 mg), [a-32 P]-UTP radiolabeled RNA probes and human SOCS RPA kit (BD Biosciences, San Diego, CA, USA) as recommended by manufacturer.
Exposure of HCC1937 cells to ionizing radiation Cells were grown to approximately 70% confluency and replated at a density of 3 Â 10 6 cells per dish in media containing 0.5% albumin but without growth factors. After 12 h incubation at 371C, media was aspirated and cells were g-irradiated at 10 Gy in a Gammacell 40 Exactor 137 Cs g-radiation source (Nordion, Ontario, Canada). Subsequently, the cells were incubated in their respective media at 371C for 2 h. Unirradiated cells were used as controls.
Western blot analysis and electrophoretic mobility shift assay Western blotting and electrophoretic mobility shift assay (EMSA) were performed as previously described (Yu et al., 2004) . Brief description of the procedures and sources of antibodies and probes used are published as supporting information on the Oncogene website.
Statistical analysis
The Student's t-test was performed on the data presented. P-values p0.05 are considered statistically significant and indicated by an asterisk (*) in Figures 1b and 5c .
